Affiliation:
1. From the Department of Physiology and Biophysics, Institute of Biomedical Sciences, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Abstract
In the coarctation hypertension model, we showed both dissociation of plasma renin activity from cardiovascular-induced effects and the reversal of hypertension-induced responses by losartan. In this study, we investigated the effects of hypertension on the expression of brain renin-angiotensin system components and the simultaneous functional responses and effects of long-term angiotensin II (AT) receptor blockade on these responses. Rats were given vehicle or losartan for 9 days and subjected to subdiaphragmatic aortic constriction or sham surgery after 4 days of treatment. On the fifth postsurgical day, pressure and heart rate were measured in the conscious state; the brain was perfused and removed afterward. Sequential slices of brainstem were hybridized with
35
S-oligodeoxynucleotide probes for angiotensinogen, AT
1A
, and AT
1B
receptors and processed for autoradiography and densitometry. In vehicle-treated rats, hypertension was accompanied by tachycardia and marked increments in angiotensinogen and AT
1A
mRNA expression in the cardiovascular system–controlling brainstem areas. In the nucleus tractus solitarii, AT
1A
density was correlated with both pressure and heart rate values (
P
<0.01), whereas angiotensinogen levels were correlated with pressure only (
P
<0.05). Losartan did not change the pressure of hypertensive rats (142±4 versus 146±2 mm Hg, losartan versus vehicle) and the hypertension-induced angiotensinogen mRNA expression but did block both tachycardic response and hypertension-induced AT
1A
mRNA expression. Hypertension and losartan did not change AT
1B
mRNA expression. The hypertension-induced positive feedback on angiotensinogen and AT
1A
mRNA expression supports the concept of a permissive role for brain angiotensin II in orchestrating circulatory responses during the development of hypertension. These data also explain the efficacy of long-term AT
1
receptor blockade to reverse hypertension-induced effects.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献